Pfizer picks GLP-1 tablet winner: Danuglipron for PhIII
Pfizer chief Mikael Dolsten told analysts last month that the Big Pharma would “cherry-pick the winner” between its two mid-stage oral GLP-1s. The drugmaker has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
